- The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited's HCM amdizalisib (HMPL-689).
- The selective and potent PI3Kδ inhibitor is being developed for relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin's lymphoma (NHL).
- Updated preliminary results from the ongoing Phase Ib expansion study in China will be presented as a Proffered Paper at the 2021 ESMO (European Society for Medical Oncology) Congress on September 20.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: HCM stock is up 3.17% at $40.08 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
